{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:31:56Z","timestamp":1785882716317,"version":"3.56.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The worldwide shortage of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while the pandemic still remains uncontrolled has led many countries to the dilemma of whether or not to vaccinate previously infected persons. Understanding the level of protection conferred by previous infection compared with that of vaccination is important for policy-making. We analyzed an updated individual-level database of the entire population of Israel to assess the protection provided by both prior infection and vaccination in preventing subsequent SARS-CoV-2 infection, hospitalization with coronavirus disease 2019 (COVID-19), severe disease, and death due to COVID-19. Outcome data were collected from December 20, 2020, to March 20, 2021. Vaccination was highly protective, with overall estimated effectiveness of 94.5% (95% confidence interval (CI): 94.3, 94.7) for documented infection, 95.8% (95% CI: 95.2, 96.2) for hospitalization, 96.3% (95% CI: 95.7, 96.9) for severe illness, and 96.0% (95% CI: 94.9, 96.9) for death. Similarly, the overall estimated level of protection provided by prior SARS-CoV-2 infection was 94.8% (95% CI: 94.4, 95.1) for documented infection, 94.1% (95% CI: 91.9, 95.7) for hospitalization, and 96.4% (95% CI: 92.5, 98.3) for severe illness. Our results should be considered by policy-makers when deciding whether or not to prioritize vaccination of previously infected adults.<\/jats:p>","DOI":"10.1093\/aje\/kwac060","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T15:06:40Z","timestamp":1648393600000},"page":"1420-1428","source":"Crossref","is-referenced-by-count":15,"title":["Similarity of Protection Conferred by Previous SARS-CoV-2 Infection and by BNT162b2 Vaccine: A 3-Month Nationwide Experience From Israel"],"prefix":"10.1093","volume":"191","author":[{"given":"Yair","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Woodbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Fluss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Yaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnona","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"27","key":"2022080311000555300_ref1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022080311000555300_ref2","article-title":"Covid-19: Pfizer-BioNTech vaccine is rolled out in US","volume":"371","author":"Tanne","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"2022080311000555300_ref3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41577-021-00531-0","article-title":"Signals of hope: gauging the impact of a rapid national vaccination campaign","volume":"21","author":"Shilo","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2022080311000555300_ref4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41591-021-01337-2","article-title":"COVID-19 dynamics after a national immunization program in Israel","volume":"27","author":"Rossman","year":"2021","journal-title":"Nat Med"},{"key":"2022080311000555300_ref5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.cmi.2021.07.041","article-title":"COVID-19 vaccination in Israel","volume":"27","author":"Muhsen","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"10287","key":"2022080311000555300_ref6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"2022080311000555300_ref7","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"2022080311000555300_ref8","article-title":"Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities [preprint]","author":"Yelin","year":"2021","journal-title":"medRxiv"},{"issue":"6","key":"2022080311000555300_ref9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.15985","article-title":"Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization","volume":"4","author":"Chodick","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10277","key":"2022080311000555300_ref10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","volume":"397","author":"Amit","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"2022080311000555300_ref11","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJMc2101951","article-title":"BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers","volume":"384","author":"Benenson","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"2022080311000555300_ref12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41591-021-01316-7","article-title":"Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine","volume":"27","author":"Levine-Tiefenbrun","year":"2021","journal-title":"Nat Med"},{"key":"2022080311000555300_ref13","article-title":"Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2","author":"Petter","year":"2021","journal-title":"medRxiv"},{"key":"2022080311000555300_ref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"10280","key":"2022080311000555300_ref15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2022080311000555300_ref16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"issue":"10283","key":"2022080311000555300_ref17","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"2022080311000555300_ref18","author":"National Institutes of Health"},{"key":"2022080311000555300_ref19","volume-title":"Analysis of Multivariate Survival Data","author":"Hougaard","year":"2012"},{"issue":"5","key":"2022080311000555300_ref20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"2022080311000555300_ref21","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine [letter]","volume":"384","author":"Skowronski","year":"2021","journal-title":"N Engl J Med"},{"key":"2022080311000555300_ref22","volume-title":"Generalized Linear Models: With Applications in Engineering and the Sciences","author":"Myers","year":"2012"},{"key":"2022080311000555300_ref23","article-title":"Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: a three-month nationwide experience from Israel [preprint]","author":"Goldberg","year":"2021","journal-title":"medRxiv"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwac060\/43858671\/kwac060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/191\/8\/1420\/45225143\/kwac060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/191\/8\/1420\/45225143\/kwac060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T07:00:46Z","timestamp":1659510046000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/191\/8\/1420\/6556183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,3,30]]},"published-print":{"date-parts":[[2022,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwac060","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.20.21255670","asserted-by":"object"}]},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,3,30]]}}}